Article
Rheumatology
Balazs Odler, Regina Riedl, Philipp Gauckler, Jae Il Shin, Johannes Leierer, Peter A. Merkel, William St Clair, Fernando Fervenza, Duvuru Geetha, Paul Monach, David Jayne, Rona M. Smith, Alexander Rosenkranz, Ulrich Specks, John H. Stone, Andreas Kronbichler
Summary: This study aimed to identify risk factors associated with severe infections in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV). The use of low-dose TMP/SMX was found to be associated with a reduced risk of severe infections in patients treated with either rituximab (RTX) or cyclophosphamide (CYC)/azathioprine (AZA). Reduced B cell subpopulations at the start of treatment may be a useful indicator of reduced immunocompetence.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Rona M. Smith, Rachel B. Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Al-jayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Luqmani, Carol McAlear, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L. Rhee, Robert Spiera, Antoine G. Sreih, Vladamir Tesar, Giles Walters, Caroline Wroe, David Jayne, Peter A. Merkel
Summary: Following remission induction with rituximab, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Naomi A. Amudala, Sara Boukhlal, Brittany Sheridan, Carol A. Langford, Abdallah Geara, Peter A. Merkel, Divi Cornec
Summary: Obinutuzumab appears to be a safe and efficacious therapy for patients with ANCA-associated vasculitis who have had refractory disease or a history of anaphylaxis to rituximab. Prospective studies comparing rituximab to obinutuzumab in ANCA-associated vasculitis patients are warranted.
Article
Urology & Nephrology
Charles Ronsin, Marie Georges, Agnes Chapelet-Debout, Jean-Francois Augusto, Vincent Audard, Ludivine Lebourg, Sebastien Rubin, Thomas Quemeneur, Pierre Bataille, Alexandre Karras, Eric Daugas, Dimitri Titeca-Beauport, Jean-Jacques Boffa, Cecile Vigneau, Jean-Michel Halimi, Corinne Isnard-Bagnis, Sandrine Durault, Eric Renaudineau, Frank Bridoux, Angelo Testa, Moglie Le Quintrec, Karine Renaudin, Fadi Fakhouri
Summary: Within the spectrum of ANCA-negative PING, infection and malignancy-associated forms represent distinct clinical subsets. Despite immunosuppressive treatments, ANCA-negative PING remains a severe form of vasculitis with high morbidity and mortality rates.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Review
Immunology
Savino Sciascia, Claudio Ponticelli, Dario Roccatello
Summary: This review presents the pathogenic mechanisms and new therapeutic approaches for anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV).
AUTOIMMUNITY REVIEWS
(2022)
Article
Immunology
Jack Arnold, Edward M. Vital, Shouvik Dass, Aamir Aslam, Andy C. Rawstron, Sinisa Savic, Paul Emery, Md Yuzaiful Md Yusof
Summary: The study found that the time to relapse after rituximab treatment for ANCA-associated vasculitis varies, and a personalized retreatment strategy can reduce unnecessary retreatments. Factors associated with longer relapse time include concomitant immunosuppressant use, achieving complete response, and naive B-cell repopulation at 6 months.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jack Arnold, Edward M. Vital, Shouvik Dass, Aamir Aslam, Andy C. Rawstron, Sinisa Savic, Paul Emery, Md Yuzaiful Md Yusof
Summary: Based on this study, all AAV patients should be prescribed oral immunosuppressants along with rituximab treatment. Patients with incomplete response or inadequate naive B-cell repopulation should be retreated at 6 months. Patients with complete response and adequate naive repopulation do not require fixed retreatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Elena Treppo, Marco Binutti, Roberto Agarinis, Salvatore De Vita, Luca Quartuccio
Summary: Antineutrophil cytoplasmatic antibody-associated vasculitis is a rare autoimmune disease that can be effectively treated with RTX, which has shown to be both effective and safe in inducing and maintaining remission. Optimizing RTX-based treatment strategies is a key focus of current AAV research.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Transplantation
Alexander R. Rosenkranz, Vladimir Tesar
Summary: As precision medicine initiatives emerge, the treatment of lupus nephritis and ANCA vasculitis is moving towards personalized approaches. The development of more accurate histopathological classification systems for LN allows for better disease categorization and targeted therapies, while a better understanding of LN pathophysiology opens up new opportunities for individualized treatments. Though advances have been made, incorporating molecular and genetic markers into diagnostic and treatment algorithms is still a goal in achieving true precision medicine.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Article
Rheumatology
Leo Segelmark, Luis Flores-Suarez, Aladdin Mohammad
Summary: Severe infections are common following RTX treatment, with older age at time of RTX treatment independently predicting severe infections. The majority of severe infections occur within the first year of RTX treatment.
Article
Rheumatology
Mark E. McClure, Yajing Zhu, Rona M. Smith, Seerapani Gopaluni, Joanna Tieu, Tasneem Pope, Karl Emil Kristensen, David R. W. Jayne, Jessica Barrett, Rachel B. Jones
Summary: This study aimed to develop relapse and infection risk prediction models for patients with ANCA-associated vasculitis receiving rituximab maintenance therapy. While the models lacked the power to discriminate risk between individual patients, they were able to assign patients into risk groups, which may help guide decisions regarding the potential benefit of ongoing rituximab treatment. Prospective multi-centre validation studies are recommended before using these prediction models in practice.
Article
Rheumatology
Fadi Kharouf, John Moshe Gomori, Chamutal Gur
Summary: We present the case of a 65-year-old female patient with bilateral hearing loss, otalgia, and hyperacusis. Imaging tests revealed a diffuse infiltrative skull base process, leading to the diagnosis of ANCA-associated vasculitis. Despite unsuccessful treatments with corticosteroids, azathioprine, and cyclophosphamide, rituximab showed impressive clinical and radiologic improvement.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H. Schirmer, Alvise Berti, Daniel Blockmans, Maria C. Cid, Julia U. Holle, Nicole Hollinger, Omer Karadag, Andreas Kronbichler, Mark A. Little, Raashid A. Luqmani, Alfred Mahr, Peter A. Merkel, Aladdin J. Mohammad, Sara Monti, Chetan B. Mukhtyar, Jacek Musial, Fiona Price-Kuehne, Marten Segelmark, Y. K. Onno Teng, Benjamin Terrier, Gunnar Tomasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne
Summary: Since the publication of the EULAR recommendations for the management of AAV in 2016, several clinical trials have been conducted that have the potential to change clinical care. A systematic literature review and expert opinions were used to modify existing recommendations and create new ones. The recommendations provide updated guidance on AAV management.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Shunsuke Furuta, Daiki Nakagomi, Yoshihisa Kobayashi, Masaki Hiraguri, Takao Sugiyama, Koichi Amano, Takeshi Umibe, Hajime Kono, Kazuhiro Kurasawa, Yasuhiko Kita, Ryutaro Matsumura, Yuko Kaneko, Keita Ninagawa, Keiju Hiromura, Shin-ichiro Kagami, Yosuke Inaba, Hideki Hanaoka, Kei Ikeda, Hiroshi Nakajima, LoVAS collaborators
Summary: The LoVAS trial compared the efficacy of reduced-dose and conventional high-dose glucocorticoid regimens plus rituximab in the treatment of antineutrophil cytoplasm antibody-associated vasculitis, and found no significant difference in remission induction rates between the two groups. However, the reduced-dose group had a lower rate of serious adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Transplantation
Laura S. van Dam, Ebru Dirikgil, Edwin W. Bredewold, Argho Ray, Jaap A. Bakker, Cees van Kooten, Ton J. Rabelink, Yoe K. Onno Teng
Summary: In AAV patients treated with RTX, ANCA and B-cell status were predictive of the majority of relapses, and specifically their absence strongly predicted a relapse-free status. Monitoring ANCA and B-cell levels could guide therapeutic decisions to prevent relapses in these patients.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Article
Medicine, General & Internal
Helen Erlandsson, Abdul Rashid Qureshi, Jonaz Ripsweden, Ida Haugen Lofman, Magnus Soderberg, Lars Wennberg, Torbjorn Lundgren, Annette Bruchfeld, Torkel B. Brismar, Peter Stenvinkel
Summary: This study investigated the impact of medial calcification on cardiovascular events (CVE) and mortality in patients starting on kidney failure replacement therapy. Moderate to severe medial calcification in the arteria epigastrica was associated with higher mortality and increased risk of CVE. The medial calcification score could be a reliable method to identify patients with high and low risk of CVE and mortality following kidney transplantation.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Transplantation
Hans-Joachim Anders, Jerome Loutan, Annette Bruchfeld, Gema M. Fernandez-Juarez, Juergen Floege, Dimitrios Goumenos, Kultigin Turkmen, Cees van Kooten, Eleni Frangou, Kate Stevens, Andreas Kronbichler, Marten Segelmark, Vladimir Tesar
Summary: This article presents the updated guidelines on the management of lupus nephritis (LN) released by the European League for Rheumatism (EULAR) and other organizations. The article compares the differences between these guidelines and highlights their significance in LN management.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Transplantation
Davide Viggiano, Annette Bruchfeld, Sol Carriazo, Antonio de Donato, Nicole Endlich, Ana Carina Ferreira, Andreja Figurek, Denis Fouque, Casper F. M. Franssen, Konstantinos Giannakou, Dimitrios Goumenos, Ewout J. Hoorn, Dorothea Nitsch, Alberto Ortiz, Vesna Pesic, Daiva Rastenyte, Maria Jose Soler, Merita Rroji, Francesco Trepiccione, Robert J. Unwin, Carsten A. Wagner, Andrzej Wiecek, Miriam Zacchia, Carmine Zoccali, Giovambattista Capasso
Summary: Kidney function involves glomerular filtration and tubular function. Chronic kidney disease is diagnosed with a persistent decrease in glomerular filtration rate. While glomerular injury is a major cause of CKD, predominant tubular injury is typically non-proteinuric.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Urology & Nephrology
Annette Bruchfeld, Hasan Magin, Patrick Nachman, Samir Parikh, Richard Lafayette, Antonia Potarca, Shichang Miao, Pirow Bekker
Summary: This study evaluated the safety and efficacy of avacopan in IgAN patients with persistent proteinuria despite maximally tolerated drug therapy. Results showed numerical improvement in proteinuria in three out of seven patients with a 50% improvement. Longer treatment duration may be needed for maximal benefit.
CLINICAL KIDNEY JOURNAL
(2022)
Review
Transplantation
Kate Stevens, Eleni Frangou, Jae Il Shin, Hans-Joachim Anders, Annette Bruchfeld, Ulf Schoenermarck, Thomas Hauser, Kerstin Westman, Gema M. Fernandez-Juarez, Juergen Floege, Dimitrios Goumenos, Kultigin Turkmen, Cees van Kooten, Stephen P. McAdoo, Vladimir Tesar, Marten Segelmark, Duvuru Geetha, David R. W. Jayne, Andreas Kronbichler
Summary: Patients with immune-mediated kidney diseases have lower immune response to COVID-19 vaccines, related to immunosuppression or comorbidities. Timing between medication use and vaccine administration affects the level of immune response. The emergence of new variants and waning of vaccine-induced immunity highlight the importance of booster doses and mutant-proof vaccines. COVID-19 vaccines are safe, but further research is needed to determine their association with immune-mediated kidney diseases.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Transplantation
Anna Levin, Angelina Schwarz, Jenny Hulkko, Liqun He, Ying Sun, Peter Barany, Annette Bruchfeld, Maria Herthelius, Lars Wennberg, Kerstin Ebefors, Jaakko Patrakka, Christer Betsholtz, Jenny Nystrom, Johan Molne, Kjell Hultenby, Anna Witasp, Annika Wernerson
Summary: This study found that levels of Dendrin mRNA were higher in IgAN patients, and the relative nuclear protein concentration was increased, both of which were associated with a slower disease progression and milder histopathological changes in patients with IgAN/IgAV.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Rheumatology
A. Antovic, A. Bruchfeld, J. Ekland, B. Lovstrom, A. Hugelius, O. Borjesson, A. Knight, I Gunnarsson
Summary: This study analysed the risk factors and outcomes of COVID-19 in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). The results showed that impaired kidney function and more intense immunosuppressive therapy were significant risk factors for severe COVID-19 in AAV patients. The findings highlight the importance of optimal AAV treatment in a pandemic situation and the need for continued protection, mitigation strategies, and effective vaccination for AAV patients.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Manuel Alfredo Podesta, Federica Mescia, Anna Ricchiuto, Rona Smith, Martina Tedesco, Matthias Arnaldo Cassia, Julia Holle, Renato Alberto Sinico, Annette Bruchfeld, Iva Gunnarsson, Sophie Ohlsson, Bo Baslund, Zdenka Hruskova, Vladimir Tesar, Gianmarco Sabiu, Maurizio Gallieni, Maria C. Cid, Augusto Vaglio, Lorraine Harper, Mario Cozzolino, Francesco Scolari, David Jayne, Federico Alberici
Summary: This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab, and the results showed that hypogammaglobulinemia is common in AAV patients treated with rituximab, and lower IgG levels are associated with severe infections. Age and higher glucocorticoid doses increase the risk of hypogammaglobulinemia in these patients.
Review
Urology & Nephrology
Balazs Odler, Annette Bruchfeld, Jennifer Scott, Duvuru Geetha, Mark A. Little, David R. W. Jayne, Andreas Kronbichler
Summary: This review focuses on the kidney survival of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). It discusses the potential for kidney recovery, the influence of various factors, and the potential improvement in prediction through modern approaches such as kidney biopsies, blood and urine markers, and patient characteristics. The review emphasizes the need for well-studied surrogate markers to predict renal outcome in AAV and highlights the limitations of traditional markers. It suggests that refinement of existing markers and the incorporation of novel approaches could significantly improve prognostication.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Transplantation
Martin Windpessl, Myrto Kostopoulou, Richard Conway, Ilay Berke, Annette Bruchfeld, Maria Jose Soler, Martina Sester, Andreas Kronbichler
Summary: The COVID-19 pandemic has highlighted our limited understanding of infectious complications and strategies to mitigate severe infections in patients with glomerular diseases. This review provides an overview of six different infectious complications commonly encountered in these patients and focuses on recent advancements in vaccine development and specific antimicrobial prophylaxis.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Rheumatology
Diana Ekman, Bengt Sennblad, Ann Knight, Asa Karlsson, Solbritt Rantapaa-Dahlqvist, Ewa Berglin, Bernd Stegmayr, Bo Baslund, Oyvind Palm, Hilde Haukeland, Iva Gunnarsson, Annette Bruchfeld, Marten Segelmark, Sophie Ohlsson, Aladdin J. Mohammad, Anna Svard, Rille Pullerits, Hans Herlitz, Annika Soderbergh, Roald Omdal, Roland Jonsson, Lars Ronnblom, Per Eriksson, Kerstin Lindblad-Toh, Johanna Dahlqvist
Summary: The study aims to identify and genetically characterize subgroups of patients with ANCA-associated vasculitides (AAV) based on sex and ANCA subtype. The research analyzed a SNP dataset derived from DNA sequencing and genotyping of AAV cases and controls. The results showed that there are differences in genetic predisposition and disease mechanisms between males and females with MPO-ANCA-positive AAV, and that double ANCA-positive AAV cases are genetically similar to PR3-ANCA-positive cases, providing implications for clinical follow-up and treatment.
Article
Transplantation
Julia Wijkstrom, Aurora Caldinelli, Annette Bruchfeld, Alexandra Nowak, Angelica Artborg, Maria Stendahl, Marten Segelmark, Bengt Lindholm, Rino Bellocco, Helena Rydell, Marie Evans
Summary: Kidney replacement therapy (KRT) patients in Sweden, who were prioritized for vaccination, experienced reduced hospitalization and mortality rates after vaccination, while kidney transplant recipients (KTRs) did not see the same reduction.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Editorial Material
Transplantation
Eleni Frangou, Annette Bruchfeld, Gema M. Fernandez-Juarez, Juergen Floege, Dimitrios Goumenos, Sarah M. Moran, Stefanie Steiger, Kate Stevens, Kultigin Turkmen, Andreas Kronbichler
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Urology & Nephrology
Gaye Hafez, Jolanta Malyszko, Aleksandra Golenia, Aleksandra Klimkowicz-Mrowiec, Ana Carina Ferreira, Mustafa Arici, Annette Bruchfeld, Dorothea Nitsch, Ziad A. Massy, Marion Pepin, Giovambattista Capasso, Laila-Yasmin Mani, Sophie Liabeuf
Summary: There is evidence that chronic kidney disease is a risk factor for cognitive impairment, possibly due to vascular damage, blood-brain barrier disruption, and uremic toxins. Medication regimens for CKD patients can be complex due to comorbidities. Common medications used in CKD treatment may have negative effects on cognition.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Rheumatology
Sara Brolin, Elisabet Welin, Bjorn Lovstrom, Annette Bruchfeld, Iva Gunnarsson, Susanne Pettersson
Summary: This study revealed significant educational needs among AAV patients, with women and those with shorter disease duration expressing higher needs. Increased education for patients with AAV may result in improved self-care and treatment adherence.
RHEUMATOLOGY ADVANCES IN PRACTICE
(2022)